BRCA2 and breast carcinoma: Of a total 131 breast cancer sera analyzed, 15.3% (20/131) was shown to have autoantibody to PARP1, 19.1% (25/131) was shown to have autoantibody to BRCA1, 36.6% (48/131) was shown to BRCA2.